請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4065
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 許文明(Wen-Ming Hsu),林凱信(Kai-Hsin Lin),廖永豐(Yung-Feng Liao) | |
dc.contributor.author | Yen-Lin Liu | en |
dc.contributor.author | 劉彥麟 | zh_TW |
dc.date.accessioned | 2021-05-13T09:20:26Z | - |
dc.date.available | 2020-08-26 | |
dc.date.available | 2021-05-13T09:20:26Z | - |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-22 | |
dc.identifier.citation | 1. Yang CP, Hung IJ, Jaing TH, Chang WH. Cancers in infancy: percent distribution and incidence rates. Acta Paediatr Taiwan. 2006;47(6):273-277.
2. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202-2211. 3. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999;86(2):364-372. 4. Hoehner JC, Gestblom C, Hedborg F, Sandstedt B, Olsen L, Pahlman S. A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage. Lab. Invest. 1996;75(5):659-675. 5. Hiyama E, Iehara T, Sugimoto T, et al. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study. Lancet. 2008;371(9619):1173-1180. 6. Woods WG, Tuchman M, Robison LL, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet. 1996;348(9043):1682-1687. 7. Segi M. Cancer Mortality for Selected Sites in 24 Countries (1950-57). Sendai, Japan: Department of Public Health, Tohoku University of Medicine; 1960. 8. Henderson TO, Bhatia S, Pinto N, et al. Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study. J. Clin. Oncol. 2011;29(1):76-82. 9. Liu YL, Lo WC, Chiang CJ, et al. Incidence of cancer in children aged 0-14 years in Taiwan, 1996-2010. Cancer Epidemiol. 2015;39(1):21-28. 10. Caiulo VA, Caiulo S, Gargasole C, et al. Ultrasound mass screening for congenital anomalies of the kidney and urinary tract. Pediatr. Nephrol. 2012. 11. Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med. 2004;45(7):1172-1188. 12. Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. New Engl J Med. 2010;363(14):1313-1323. 13. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J. Clin. Oncol. 2009;27(2):289-297. 14. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005;23(27):6459-6465. 15. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009;27(7):1026-1033. 16. Tomioka N, Oba S, Ohira M, et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene. 2008;27(4):441-449. 17. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27(2):298-303. 18. Simon T, Haberle B, Hero B, von Schweinitz D, Berthold F. Role of Surgery in the Treatment of Patients With Stage 4 Neuroblastoma Age 18 Months or Older at Diagnosis. J. Clin. Oncol. 2013;31(6):752-758. 19. Simon T, Hero B, Benz-Bohm G, von Schweinitz D, Berthold F. Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial. Pediatr Blood Cancer. 2008;50(5):965-969. 20. Cecchetto G, Mosseri V, De Bernardi B, et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J. Clin. Oncol. 2005;23(33):8483-8489. 21. Liu YL, Miser JS, Hsu WM. Risk-directed therapy and research in neuroblastoma. J Formos Med Assoc. 2014;113(12):887-889. 22. Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013;14(10):999-1008. 23. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324-1334. 24. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 2013;45(3):279-284. 25. La Quaglia MP, Kushner BH, Su W, et al. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg. 2004;39(3):412-417; discussion 412-417. 26. Hsu WM, Jen YM, Lee H, et al. The influence of biologic factors on the surgical decision in advanced neuroblastoma. Ann Surg Oncol. 2006;13(2):238-244. 27. Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011;261(1):243-257. 28. Kushner BH, Kramer K, Modak S, Cheung NK. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol. 2009;27(7):1041-1046. 29. Dubois SG, Geier E, Batra V, et al. Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. Int. J. Mol. Imag. 2012;2012:250834. 30. Yanik GA, Parisi MT, Shulkin BL, et al. Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group. J. Nucl. Med. 2013;54(4):541-548. 31. Decarolis B, Schneider C, Hero B, et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the cologne interscore comparison study. J. Clin. Oncol. 2013;31(7):944-951. 32. Matthay KK, Shulkin B, Ladenstein R, et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010;102(9):1319-1326. 33. Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer. 2014;50(4):801-815. 34. French S, DuBois SG, Horn B, et al. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr. Blood Cancer. 2013;60(5):879-884. 35. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25(9):1054-1060. 36. Choi YJ, Hwang HS, Kim HJ, et al. (18)F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy. Ann Nucl Med. 2014;28(4):304-313. 37. Papathanasiou ND, Gaze MN, Sullivan K, et al. 18F-FDG PET/CT and 123I-Metaiodobenzylguanidine Imaging in High-Risk Neuroblastoma: Diagnostic Comparison and Survival Analysis. J Nucl Med. 2011;52(4):519-525. 38. Melzer HI, Coppenrath E, Schmid I, et al. 123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma. Eur. J. Nucl. Med. Mol. Imaging. 2011;38(9):1648-1658. 39. Chawla M, Kumar R, Agarwala S, Bakhshi S, Gupta DK, Malhotra A. Role of positron emission tomography-computed tomography in staging and early chemotherapy response evaluation in children with neuroblastoma. Indian J Nucl Med. 2010;25(4):147-155. 40. Taggart DR, Han MM, Quach A, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009;27(32):5343-5349. 41. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50(8):1237-1243. 42. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol. 2001;19(14):3397-3405. 43. Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996;199(3):743-750. 44. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer. 2011;11(5):325-337. 45. Vallabhajosula S. 18F-Labeled Positron Emission Tomographic Radiopharmaceuticals in Oncology: An Overview of Radiochemistry and Mechanisms of Tumor Localization. Seminars in Nuclear Medicine. 2007;37(6):400-419. 46. Kumakura Y, Cumming P. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist. 2009;15(6):635-650. 47. Minn H, Kauhanen S, Seppanen M, Nuutila P. 18F-FDOPA: a multiple-target molecule. J Nucl Med. 2009;50(12):1915-1918. 48. Gilbert J, Haber M, Bordow SB, Marshall GM, Norris MD. Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies. Am J Pathol. 1999;155(1):17-21. 49. Bozzi F, Luksch R, Collini P, et al. Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma. Diagn Mol Pathol. 2004;13(3):135-143. 50. Geerts D, Koster J, Albert D, et al. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. International journal of cancer. Journal international du cancer. 2010;126(9):2012-2024. 51. Koster J. R2: microarray analysis and visualization platform. http://r2.amc.nl. 52. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11(8):1466-1477. 53. Tsai HY, Hsi BL, Hung IJ, et al. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections. Hum Pathol. 2004;35(11):1397-1403. 54. Schleiermacher G, Mosseri V, London WB, et al. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br. J. Cancer. 2012;107(8):1418-1422. 55. Chang HH, Lee H, Hu MK, et al. Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma. Clin Cancer Res. 2010;16(17):4411-4420. 56. Yang AS, Chiang TC, Shen LH. Acute intravenous injection toxicity study of MIBG in mice. Drug Chem Toxicol. 2010;33(1):17-19. 57. de Vries EFJ, Luurtsema G, Brussermann M, Elsinga PH, Vaalburg W. Fully automated synthesis module for the high yield one-pot preparation of 6-[18F]fluoro-l-DOPA. Appl Radiat Isot. 1999;51(4):389-394. 58. Hsu WM, Hsieh FJ, Jeng YM, et al. Calreticulin expression in neuroblastoma--a novel independent prognostic factor. Ann Oncol. 2005;16(2):314-321. 59. Fischer M, Skowron M, Berthold F. Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. J Mol Diagn. 2005;7(1):89-96. 60. Teitz T, Stanke JJ, Federico S, et al. Preclinical models for neuroblastoma: establishing a baseline for treatment. PLoS One. 2011;6(4):e19133. 61. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. The EMBO journal. 1997;16(11):2985-2995. 62. Haraguchi S, Nakagawara A. A simple PCR method for rapid genotype analysis of the TH-MYCN transgenic mouse. PLoS One. 2009;4(9):e6902. 63. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 1989;24(3):148-154. 64. Hsu WC, Tzen KY, Huy PT, Duet M, Yeh TH. An animal model of central auditory pathway imaging in the rat brain by high resolution small animal positron emission tomography. Acta Otolaryngol. 2009;129(4):423-428. 65. Rasmuson A, Segerstrom L, Nethander M, et al. Tumor Development, Growth Characteristics and Spectrum of Genetic Aberrations in the TH-MYCN Mouse Model of Neuroblastoma. PLoS One. 2012;7(12):e51297. 66. Cistaro A, Quartuccio N, Caobelli F, et al. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma. Nucl Med Rev Cent East Eur. 2015;18(2):102-106. 67. Zhang H, Huang R, Cheung NK, et al. Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res. 2014;20(8):2182-2191. 68. Vaidyanathan G, Affleck DJ, Zalutsky MR. (4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography. J. Med. Chem. 1994;37(21):3655-3662. 69. Gershon TR, Shirazi A, Qin LX, Gerald WL, Kenney AM, Cheung NK. Enteric neural crest differentiation in ganglioneuromas implicates Hedgehog signaling in peripheral neuroblastic tumor pathogenesis. PLoS One. 2009;4(10):e7491. 70. Bourdeaut F, Janoueix-Lerosey I, Lucchesi C, et al. Cholinergic switch associated with morphological differentiation in neuroblastoma. J Pathol. 2009;219(4):463-472. 71. Zirath H, Frenzel A, Oliynyk G, et al. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc. Natl. Acad. Sci. U. S. A. 2013;110(25):10258-10263. 72. Piccardo A, Puntoni M, Lopci E, et al. Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. Eur. J. Nucl. Med. Mol. Imaging. 2014;41(6):1046-1056. 73. Lee JW, Cho A, Yun M, Lee JD, Lyu CJ, Kang WJ. Prognostic value of pretreatment FDG PET in pediatric neuroblastoma. Eur J Radiol. 2015;84(12):2633-2639. 74. Kurland BF, Muzi M, Peterson LM, et al. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. J Nucl Med. 2016;57(2):226-230. 75. Patra KC, Wang Q, Bhaskar PT, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24(2):213-228. 76. Qing G, Skuli N, Mayes PA, et al. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. Cancer Res. 2010;70(24):10351-10361. 77. Palaskas N, Larson SM, Schultz N, et al. 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res. 2011;71(15):5164-5174. 78. Kocak H, Ackermann S, Hero B, et al. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma. Cell Death Dis. 2013;4:e586. 79. Chuang JH, Chou MH, Tai MH, et al. 2-Deoxyglucose treatment complements the cisplatin- or BH3-only mimetic-induced suppression of neuroblastoma cell growth. Int. J. Biochem. Cell. Biol. 2013;45(5):944-951. 80. Huang CC, Wang SY, Lin LL, et al. Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice. Dis Model Mech. 2015;8(10):1247-1254. 81. Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3(3):308-323. 82. Bean JF, Qiu YY, Yu S, Clark S, Chu F, Madonna MB. Glycolysis inhibition and its effect in doxorubicin resistance in neuroblastoma. J Pediatr Surg. 2014;49(6):981-984; discussion 984. 83. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. 84. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12-27. 85. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-1073. 86. Mertz JA, Conery AR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. U. S. A. 2011;108(40):16669-16674. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4065 | - |
dc.description.abstract | 神經母細胞瘤(neuroblastoma;NB)起源於交感神經,好發於嬰幼兒。過半病童診斷時已有多處轉移,預後不佳。因此,臨床上需使用多種影像檢查來進行診斷、分期與追蹤。本研究欲以分子影像探討神經母細胞瘤的腫瘤行為特徵。首先,我們運用氟多巴正子造影(18F-FDOPA PET)在身體各部位診斷神經母細胞瘤;其敏感度達97.6%(95%信賴區間87.4%–99.9%),特異性87.5%(47.3%–99.7%),可與目前黃金標準的MIBG核子醫學掃描(123I-MIBG scintigraphy)或去氧葡萄糖正子造影(18F-FDG PET)互補。接下來,由2007年至2014年新診斷神經母細胞瘤的個案中,分析主要腫瘤FDG與FDOPA正子影像的最大標準吸收值(SUVmax),發現年齡較大、分期較嚴重、MYCN放大等較惡性特徵者,皆具有FDG吸收值較高、FDOPA吸收值較低的現象(所有P值 < 0.02)。利用接收者操作特徵曲線(receiver operating characteristics)統計,我們將FDG吸收值 ≥ 3.31及FDOPA吸收值 < 4.12定義為「正子影像極高危險群(PET ultra-high-risk)」,可區分出節段性染色體變化或MYCN致癌基因放大等高度惡性的基因體類型,為無事件存活率較差的獨立預測因子(多變數分析之風險比值 [HR] = 4.9 [1.9–30.1],P = 0.012),且較不易以外科手術完整切除(gross total resection;切除率46%相對於100%,P = 0.04)。此外,FDG與FDOPA吸收值的比值(G:D)與糖解作用HK2激酶基因表現呈正相關(Spearman’s ρ = 0.86,P < 0.0001)、與多巴代謝酵素DDC基因表現呈負相關(ρ = -0.58;P = 0.02),表示PET-UHR腫瘤很可能具有較強的糖解作用活性及較差的神經代謝分化。最後,我們整合小動物超音波與正子造影,以Th-MYCN基因轉殖小鼠發展臨床前試驗平臺,發現其腫瘤75%為FDG吸收值較高、FDOPA吸收值較低,與人類神經母細胞瘤帶有MYCN放大者相似。利用此影像評估與追蹤平臺,我們驗證了BRD4表觀基因標靶藥物可強力抑制Th-MYCN小鼠腫瘤生長,但維他命A酸分化治療則無效。總結來說,FDG與FDOPA功能性分子影像可評估神經母細胞瘤的腫瘤行為、補強現有的危險群分類系統、發展為重要的臨床前評估工具,未來可望轉譯為運用分子影像發展個人化標靶治療的新穎治療策略。 | zh_TW |
dc.description.abstract | Neuroblastoma (NB) is a devastating tumor that usually occurs in young children. More than 50% of patients are diagnosed with metastatic diseases or other high-risk features, who suffer from a dismal prognosis. Therefore, a multitude of imaging studies are required for the staging and surveillance of NB. This study aims to characterize NB tumor behavior using molecular imaging modalities. First, we showed that positron emission tomography (PET) with 18F-fluoro-dihydroxyphenylalanine (FDOPA), a radiolabeled amino acid targeting catecholamine metabolism, had a sensitivity of 97.6% (87.4%–99.9%) and a specificity of 87.5% (47.3%–99.7%) and may compliment current 123I-metaiodobenzylguanidine (123I-MIBG) and 18F-fluorodeoxyglucose (FDG) PET scans. Next, NB patients undergoing paired FDG and FDOPA PET scans at diagnosis during 2007–2014 (N = 42; median age, 2.0 years; 28 boys and 14 girls;) were evaluated for the maximum standardized uptake value (SUVmax) of FDG or FDOPA by the primary tumor, revealing that NB with older age, advanced stages, or MYCN amplification showed higher FDG and lower FDOPA SUVmax (all P < 0.02). Receiver operating characteristics analysis identified FDG SUVmax ≥ 3.31 and FDOPA SUVmax < 4.12 as an ultra-high-risk feature (PET-UHR) that distinguished the most unfavorable genomic types, i.e. segmental chromosomal alterations and/or MYCN amplification, at a sensitivity of 81.3% (54.4%–96.0%) and a specificity of 93.3% (68.1%–99.8%). Considering with age, stage, MYCN status, and anatomical image-defined risk factor, PET-UHR was an independent predictor of inferior event-free survival (multivariate hazard ratio, 4.9 [1.9–30.1]; P = 0.012) and was associated lower likelihood of gross total resection of the main tumor (46% vs. 100%; P = 0.04). Meanwhile, the ratio between FDG and FDOPA SUVmax (G:D) correlated positively with hexokinase 2 (HK2; Spearman’s ρ = 0.86, P < 0.0001) and negatively with DOPA decarboxylase (DDC; ρ = -0.58, P = 0.02) gene expression levels, suggesting higher glycolytic activity and less catecholaminergic differentiation in NB tumors taking up higher FDG and lower FDOPA. Finally, we incorporated small-animal ultrasound screening and PET imaging to build up a preclinical trial platform. We characterized the tumor latency and progression in the hemizygous Th-MYCN mice, a genetically-engineered mouse model of NB. In parallel to human NB with MYCN amplification, the majority (75%) of Th-MYCN murine NB tumors showed higher uptake of FDG and lower uptake of FDOPA. Using the imaging platform, We have validated the potent therapeutic effect of epigenetic inhibition of MYCN transcription by targeting the bromodomain BRD4 reader protein, while 13-cis-retinoic acid showed no anti-tumor activity in this model. In conclusion, the functional FDG and FDOPA PET imaging characterizes the NB tumor behavior; complements the current risk stratification systems of NB; and serves as an important part of preclinical trails. The results of this study can be translated into critical clinical knowledge of molecular imaging of NB, and may pave the way of individualized target therapy through molecular imaging. | en |
dc.description.provenance | Made available in DSpace on 2021-05-13T09:20:26Z (GMT). No. of bitstreams: 1 ntu-105-D99456003-1.pdf: 23267737 bytes, checksum: 2285106b507bcbfa114cac78c7e74dbb (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 口試委員會審定書 i
Acknowledgement 誌謝 iii 中文摘要 v Abstract vi 1. Introduction 緒論 1 1.1. Epidemiology of neuroblastoma 1 1.2. Diagnostic modalities and treatment stratification of NB 3 1.3. Clinical use of molecular imaging in NB 6 1.4. Rationale for applying FDOPA PET imaging in NB 7 1.5. Aims of this study 8 2. Material and Methods 材料與方法 9 2.1. Patient enrollment 9 2.2. Standard evaluations for NB patients 10 2.3. Risk-directed therapy 11 2.4. Acquisition of images and data analysis 11 2.5. Production of 18F-FDOPA 13 2.6. Real-time PCR analysis 14 2.7. Statistical analysis 15 2.8. Transgenic NB mouse model 16 2.9. Small animal ultrasound screening 17 2.10. Small animal PET study 18 3. Results 結果 19 3.1. Characterization of neuroblastic tumors with FDOPA PET 19 3.2. Comparison of 18F-FDOPA PET, 123I-MIBG scan, and 18F-FDG PET 20 3.3. Correlation between tumor uptake and catecholamine markers 20 3.4. FDG and FDOPA PET imaging features at initial diagnosis of NB 21 3.5. Distribution of FDG and FDOPA uptake by primary NB tumors 22 3.6. Tumor Uptake Distinguishes NB Genomic Types 23 3.7. Tumor uptake predicts surgical outcome 24 3.8. Prognostic Value of FDG and FDOPA Uptake by the Primary Tumors 25 3.9. Tumor uptake of FDG and FDOPA and relevant gene expression 26 3.10. Establishing a preclinical imaging platform for NB 26 3.11. Preclinical PET imaging in Th-MYCN mice 28 3.12. Efficacy of epigenetic inhibition of MYCN in the preclinical model 29 4. Discussion 討論 30 4.1. FDG & FDOPA PET imaging reflects the tumor biology of NB 30 4.2. The impact of molecular imaging on NB surgery 31 4.3. Overall genomic pattern predicts the molecular imaging phenotype of NB 32 4.4. Diagnostic PET imaging as a predictor of treatment outcome 33 4.5. The utility of a preclinical molecular imaging platform of NB 35 4.6. Limitations of this study 36 4.7. Conclusion 37 5. References 參考文獻 38 6. Tables 附表 48 7. Figures 附圖 55 8. Appendix: PhD Publications 修業期間發表之論文 91 | |
dc.language.iso | en | |
dc.title | 以分子影像探討神經母細胞瘤的腫瘤行為特徵 | zh_TW |
dc.title | Characterization of Neuroblastoma Tumor Behavior by Molecular Imaging | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 李心予(Hsinyu Lee),蔡有光(Yeou-Guang Tsay) | |
dc.subject.keyword | 兒童癌症,神經母細胞瘤,正子造影,分子影像,18F-FDOPA,18F-FDG,Th-MYCN基因轉殖鼠, | zh_TW |
dc.subject.keyword | Childhood cancer,neuroblastoma,positron emission tomography,molecular imaging,18F-FDG,18F-FDOPA,Th-MYCN transgenic mice, | en |
dc.relation.page | 93 | |
dc.identifier.doi | 10.6342/NTU201600303 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2016-08-22 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 轉譯醫學博士學位學程 | zh_TW |
顯示於系所單位: | 轉譯醫學博士學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf | 22.72 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。